Name in SEC filings: Roivant Sciences Ltd.
Source: ORION, orionbiotechai.com/company/ROIV, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/ROIV
IMVT-1402 · Topline/data readout · 2H 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readout2H 2026
Stage: Not stated
Public float: $9,800,000,000 · as of · SEC filing
Further updates from difficult-to-treat rheumatoid arthritis program 2H 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2H 2026
Stage: Phase 2SEC filing · “Phase 2”
Public float: $9,800,000,000 · as of · SEC filing
Topline data from Phase 2 trial in cutaneous lupus erythematosus 2H 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2H 2026
Stage: Phase 2SEC filing · “Phase 2”
Public float: $9,800,000,000 · as of · SEC filing
Topline data from Phase 2 trial in pulmonary hypertension associated with interstitial lung disease 2H 2026
10-Q · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2027
Stage: Not stated
Public float: $9,800,000,000 · as of · SEC filing
Topline data from potentially registrational trials in Graves’ disease 2027
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Topline/data readout2027
Stage: Not stated
Public float: $9,800,000,000 · as of · SEC filing
Topline data from potentially registrational trial in myasthenia gravis 2027
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| IMVT-1402Clinical results | 2H 2026“Further updates from difficult-to-treat rheumatoid arthritis program 2H 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| IMVT-1402Clinical results | 2H 2026“Topline data from Phase 2 trial in cutaneous lupus erythematosus 2H 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| IMVT-1402Clinical results | 2027“Topline data from potentially registrational trials in Graves’ disease 2027” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| IMVT-1402Clinical results | 2027“Topline data from potentially registrational trial in myasthenia gravis 2027” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| mosliciguatClinical results | 2H 2026“Topline data from Phase 2 trial in pulmonary hypertension associated with interstitial lung disease 2H 2026” Filed · 10-Q | Disclosure present SEC filing date within the stated period Filed · EX-99.1 “Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)” |
| IMVT-1402Clinical results | 2H 2026“Further updates from difficult-to-treat rheumatoid arthritis program 2H 2026” Filed · 10-K | Still within period As of Oct 19, 2026 |
| IMVT-1402Clinical results | second half of calendar year 2026“Immunovant will provide further updates on this program in the second half of calendar year 2026” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| IMVT-1402Clinical results | 2H 2026“Topline data from Phase 2 trial in cutaneous lupus erythematosus 2H 2026” Filed · 10-K | Still within period As of Oct 19, 2026 |
| IMVT-1402Clinical results | second half of calendar year 2026“IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) is fully enrolled, with topline data expected in the second half of calendar year 2026” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| IMVT-1402Clinical results | second half of calendar year 2026“Further updates on this program, as well as topline data from the fully enrolled proof-of-concept trial in cutaneous lupus erythematosus (CLE), are expected in the second half of calendar year 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| IMVT-1402Clinical results | 2027“Topline data from potentially registrational trials in Graves’ disease 2027” Filed · 10-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| IMVT-1402Clinical results | 2027“Topline data from potentially registrational trial in myasthenia gravis 2027” Filed · 10-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| mosliciguatClinical results | 2H 2026“Topline data from Phase 2 trial in pulmonary hypertension associated with interstitial lung disease 2H 2026” Filed · 10-K | Disclosure present SEC filing date within the stated period Filed · EX-99.1 “Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)” |
| mosliciguatClinical results | second half of calendar year 2026“Phase 2 PHocus study of mosliciguat in 135 patients with pulmonary hypertension associated with interstitial lung disease ( “ PH-ILD); topline data expected in the second half of calendar year 2026.” Filed · 10-K | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| mosliciguatClinical results | second half of calendar year 2026“Phase 2 PHocus study of mosliciguat in 135 patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD); topline data expected in the second half of calendar year 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| IMVT-1402Clinical results | calendar year 2027“Topline data from the potentially registrational studies of IMVT-1402 in Graves’ disease are expected in calendar year 2027.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| IMVT-1402Clinical results | 2H 2026“Topline data from Phase 2 trial in cutaneous lupus erythematosus 2H 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| IMVT-1402Clinical results | 2027“Topline data from potentially registrational trials in Graves’ disease 2027” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| IMVT-1402Clinical results | 2027“Topline data from potentially registrational trial in myasthenia gravis 2027” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| mosliciguatClinical results | 2H 2026“Topline data from Phase 2 trial in pulmonary hypertension associated with interstitial lung disease 2H 2026” Filed · 10-Q | Disclosure present SEC filing date within the stated period Filed · EX-99.1 “Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)” |
| mosliciguatClinical results | second half of calendar year 2026“Phase 2 trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease fully enrolled, with topline data expected in the second half of calendar year 2026.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| IMVT-1402Clinical results | 2027“Topline data from potentially registrational trials in Graves’ disease 2027” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| IMVT-1402Clinical results | 2027“Topline data from potentially registrational trial in myasthenia gravis 2027” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| mosliciguatClinical results | 2H 2026“Topline data from Phase 2 trial in pulmonary hypertension associated with interstitial lung disease 2H 2026” Filed · 10-Q | Disclosure present SEC filing date within the stated period Filed · EX-99.1 “Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)” |
| IMVT-1402Clinical results | 2027“Topline data from potentially registrational trials in Graves’ disease 2027” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| IMVT-1402Clinical results | 2027“Topline data from potentially registrational trial in myasthenia gravis 2027” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| mosliciguatClinical results | 2H 2026“Topline data from Phase 2 trial in pulmonary hypertension associated with interstitial lung disease 2H 2026” Filed · 10-Q | Disclosure present SEC filing date within the stated period Filed · EX-99.1 “Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)” |
| IMVT-1402Clinical results | 2027“Topline data from potentially registrational trial in myasthenia gravis 2027” Filed · 10-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| mosliciguatClinical results | 2H 2026“Topline data from Phase 2 trial in pulmonary hypertension associated with interstitial lung disease 2H 2026” Filed · 10-K | Disclosure present SEC filing date within the stated period Filed · EX-99.1 “Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)” |
| mosliciguatClinical results | 2H 2026“Topline data from Phase 2 trial in pulmonary hypertension associated with interstitial lung disease 2H 2026” Filed · 10-Q | Disclosure present SEC filing date within the stated period Filed · EX-99.1 “Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)” |
| mosliciguatClinical results | 2H 2026“Topline data from Phase 2 trial in pulmonary hypertension associated with interstitial lung disease 2H 2026” Filed · 10-Q | Disclosure present SEC filing date within the stated period Filed · EX-99.1 “Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)” |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for ROIV. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See ROIV in the calendar · Review labels and methodology